Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).

被引：4
|
作者：
Dreicer, Robert
Hoffman-Censits, Jean H.
Flaig, Thomas W.
Grande, Enrique
Balmanoukian, Ani Sarkis
von Amsberg, Gunhild
Theodore, Christine
Chowdhury, Simon
Bracarda, Sergio
Clement, Jessica Mary
Yu, Evan Y.
Kalebasty, Arash Rezazadeh
Niegisch, Guenter
Culine, Stephane
Gordon, Michael S.
Cui, Na
Mariathasan, Sanjeev
Legrand, Fatema A.
Abidoye, Oyewale O.
Petrylak, Daniel Peter
机构：
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
[2] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[3] Univ Colorado, Canc Ctr, Aurora, CO USA
[4] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
[5] Angeles Clin & Res Inst, Los Angeles, CA USA
[6] 6Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[7] Hosp Foch, Suresnes, France
[8] Guys Hosp, London, England
[9] Kings Hosp, London, England
[10] St Thomas Hosp, London, England
[11] Osped San Donato USL8, Med Oncol, Ist Toscano Tumori, Arezzo, Italy
[12] Univ Connecticut, Ctr Hlth, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA
[13] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[14] Norton Canc Inst, Louisville, KY USA
[15] Heinrich Heine Univ, Dept Urol, Dusseldorf, Germany
[16] Hop St Louis, Paris, France
[17] HonorHlth Res Inst, Pinnacle Oncol Hematol, Scottsdale, AZ USA
[18] Genentech Inc, San Francisco, CA 94080 USA
[19] Roche Genentech, San Francisco, CA USA
[20] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[21] Yale Univ, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.4515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4515
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
    Luis Perez-Gracia, Jose
    Loriot, Yohann
    Rosenberg, Jonathan E.
    Powles, Thomas
    Necchi, Andrea
    Hussain, Syed A.
    Morales-Barrera, Rafael
    Retz, Margitta M.
    Niegisch, Gunter
    Duran, Ignacio
    Theodore, Christine
    Grande, Enrique
    Shen, Xiaodong
    Wang, Jingjing
    Nelson, Betty
    Derleth, Christina L.
    van der Heijden, Michiel S.
    EUROPEAN UROLOGY, 2018, 73 (03) : 462 - 468
  • [32] Final overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy (chemo) in untreated locally advanced or metastatic urothelial carcinoma (mUC) from the Phase 3 IMvigor130 study.
    Bamias, Aristotelis
    Davis, Ian D.
    Galsky, Matt D.
    Arija, Jose Angel Arranz
    Kikuchi, Eiji
    Grande, Enrique
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    Bene-Tchaleu, Fabiola
    Mariathasan, Sanjeev
    Lee, Chooi Peng
    Bernhard, Sandrine
    De Santis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [33] Atezolizumab (atezo) plus platinum/gemcitabine (plt/gem) vs placebo plus plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130.
    Galsky, Matthew D.
    Arranz, Jose Angel
    Grande, Enrique
    De Santis, Maria
    Davis, Ian D.
    Kikuchi, Eiji
    Garcia del Muro, Xavier
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li, Jian-Ri
    O'Donnell, Peter H.
    Shen, Xiaodong
    Lee, Chooi
    Mecke, Almut
    Mariathasan, Sanjeev
    Bamias, Aristotelis
    CANCER RESEARCH, 2021, 81 (13)
  • [34] Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
    M. Sotelo
    T. Alonso-Gordoa
    P. Gajate
    E. Gallardo
    R. Morales-Barrera
    J. L. Pérez-Gracia
    J. Puente
    P. Sánchez
    D. Castellano
    I. Durán
    Clinical and Translational Oncology, 2021, 23 : 882 - 891
  • [35] Updated results of PEANUT trial: Pembrolizumab and nabpaclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
    Bottiglieri, A.
    Bravo, W. Ferrari
    Rametta, A.
    Provenzano, L.
    Raggi, D.
    Marandino, L.
    Fare, E.
    Longo, V.
    Guadalupi, V.
    Stellato, M.
    Verzoni, E.
    Sepe, P.
    Claps, M.
    Calareso, G.
    Alessi, A.
    Cattaneo, L.
    Colecchia, M.
    Procopio, G.
    Necchi, A.
    Giannatempo, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1206 - S1206
  • [36] Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC)
    Bedke, J.
    Merseburger, A. S.
    Loriot, Y.
    Castellano, D.
    Choy, E.
    Duran, I.
    Rosenberg, J.
    Petrylak, D. P.
    Dreicer, R.
    Perez-Gracia, J. L.
    Hoffman-Censits, J. H.
    Van der Heijden, M. S.
    Degaonkar, V.
    Thiebach, L.
    de Ducla, S.
    Fear, S.
    Powles, T.
    Sternberg, C. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 255 - 256
  • [37] Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC)
    Bedke, Jens
    Merseburger, Axel Stuart
    Loriot, Yohann
    Castellano, Daniel
    Choy, Ernest
    Duran, Ignacio
    Rosenberg, Jonathan E.
    Petrylak, Daniel Peter
    Dreicer, Robert
    Perez-Gracia, Jose Luis
    Hoffman-Censits, Jean H.
    Van Der Heijden, Michiel Simon
    Degaonkar, Viraj
    Thiebach, Lars
    de Ducla, Sabine
    Fear, Simon
    Powles, Thomas
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
    Galsky, Matt D.
    Grande, Enrique
    Davis, Ian D.
    De Santis, Maria
    Arija, Jose Angel Arranz
    Kikuchi, Eiji
    Mecke, Almut
    Thastrom, Ann Christine
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States
    Pal, Sumanta Kumar
    Hoffman-Censits, Jean
    Zheng, Hanzhe
    Kaiser, Constanze
    Tayama, Darren
    Bellmunt, Joaquim
    EUROPEAN UROLOGY, 2018, 73 (05) : 800 - 806
  • [40] Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.
    Galsky, Matt D.
    Bamias, Aristotelis
    Arranz Arija, Jose Angel
    Davis, Ian D.
    De Santis, Maria
    Kikuchi, Eiji
    del Muro, Xavier Garcia
    Park, Se Hoon
    De Giorgi, Ugo
    Alekseev, Boris
    Mencinger, Marina
    Izumi, Kouji
    Puente, Javier
    Li Jian-Ri
    Mecke, Almut
    Mariathasan, Sanjeev
    Banchereau, Romain
    Huang Xinhui
    Lee, Chooi Peng
    Grande, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345